SCHEMBL5175482

SCHEMBL5175482

Cc1ccc2c(/N=C/C(O)(CC3c4ccccc4CCC3C)C(F)(F)F)cccc2n1

nearest known ligand 0.37

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 5/20 0.37
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5476398 1.00 NR3C1 (0.37) NR3C1ALDH1A1
SCHEMBL5476405 1.00 NR3C1 (0.37) NR3C1ALDH1A1
SCHEMBL5470453 0.85 NR3C1 (0.41) NR3C1ALDH1A1
SCHEMBL5470464 0.85 NR3C1 (0.41) NR3C1ALDH1A1
SCHEMBL5470457 0.85 NR3C1 (0.41) NR3C1ALDH1A1
SCHEMBL5173886 0.81 NR3C1 (0.33) NR3C1
SCHEMBL5476878 0.81 NR3C1 (0.33) NR3C1
SCHEMBL5476885 0.81 NR3C1 (0.33) NR3C1
SCHEMBL5471412 0.77 NR3C1 (0.57) NR3C1ALDH1A1
SCHEMBL5930883 0.75 NR3C1 (0.33) NR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1869013-A1 SUBSTITUTED CHROMAN DERIVATIVES, METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF ANTIPHLOGISTICS Bayer Schering Pharma Aktiengesellschaft (DE) 2007-12-26 EP disclosed
US-20070129358-A1 Sbstituted chroman derivatives, processes for their preparation and their use as antiinflammatory agents SCHERING AG (DE) 2007-06-07 US disclosed
WO-2006108711-A1 SUBSTITUTED CHROMAN DERIVATIVES, METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF ANTIPHLOGISTICS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129358-A1 Sbstituted chroman derivatives, processes for their preparation and their use as antiinflammatory agents TNF, CXCL8, MPO NR3C1 83/4885ALDH1A1 1563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.